Product Information:

GABICA CR 82.5mg Tablets contain Pregabalin 82.5mg in a controlled-release (CR) formulation. Pregabalin is a gamma-aminobutyric acid (GABA) analog that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters involved in neuropathic pain, seizure activity, and anxiety.

This low-strength controlled-release formulation is primarily used for initial titration, elderly patients, or individuals with mild symptoms or renal impairment who require once-daily dosing with enhanced tolerability.

⚠️ Note: The 82.5mg strength is specifically designed for once-daily dosing and is not interchangeable with immediate-release pregabalin on a mg-per-mg basis.

Uses of (GABICA CR 82.5MG TABLETS):

1. Initial treatment of neuropathic pain (e.g., diabetic neuropathy, postherpetic neuralgia)
2. Adjunctive therapy in partial-onset seizures in sensitive or elderly patients
3. Off-label use in generalized anxiety disorder (GAD) at low doses
4. Patients with mild renal impairment requiring reduced dosing with once-daily convenience

Key Benefits of (GABICA CR 82.5MG TABLETS):

1. Once-daily dosing improves adherence, especially in elderly patients
2. Controlled-release mechanism provides steady drug levels, reducing peak-related side effects (e.g., dizziness, drowsiness)
3. Lower starting dose minimizes risk of adverse effects during initiation
4. Ideal for gradual dose escalation to higher CR strengths (e.g., 165mg or 330mg)

How To Use (GABICA CR 82.5MG TABLETS):

1. Take once daily, preferably after an evening meal (food enhances absorption).
2. Swallow whole with water—do not crush, chew, split, or dissolve (doing so destroys the controlled-release mechanism).
3. Take at the same time each day.
4. Do not stop abruptly—taper gradually under medical supervision to avoid withdrawal symptoms (insomnia, headache, nausea, or seizures).

When Not to Use (GABICA CR 82.5MG TABLETS):

Do not use if you have:

1. Hypersensitivity to pregabalin or any excipients
2. History of angioedema with pregabalin
3. Severe renal impairment (CrCl <30 mL/min)—alternative dosing required
4. Pregnancy or breastfeeding (unless clearly needed after risk-benefit assessment)

Side Effects of (GABICA CR 82.5MG TABLETS):

Common (less frequent at this dose): Mild dizziness, slight drowsiness, dry mouth, or headache.

Rare: Fatigue, mild peripheral edema, blurred vision.

Serious (very rare at low dose):

1. Angioedema (facial or throat swelling)
2. Mood changes or suicidal thoughts
3. Discontinue and seek medical help if severe reactions occur.

Dosage: (GABICA CR 82.5MG TABLETS):

1. Starting dose: 82.5mg once daily (evening)
2. May be increased after 1 week to 165mg once daily, based on response and tolerability
3. Renal impairment (CrCl 30–59 mL/min): Use with caution; may require extended dosing intervals
4. Elderly: Preferred initial CR dose due to reduced kidney function and sensitivity to CNS effects

Who It’s For (GABICA CR 82.5MG TABLETS):

1. Elderly patients initiating pregabalin therapy
2. Individuals with mild neuropathic pain or anxiety
3. Patients with mild renal impairment needing simplified dosing
4. Those transitioning from immediate-release pregabalin to once-daily CR formulation

Warnings & Precautions:

1. May still cause drowsiness—avoid driving until effects are known
2. Monitor for mood changes, even at low doses
3. Use cautiously in patients with heart failure (risk of fluid retention)
4. Risk of misuse is low but possible—prescribe responsibly

Drug Interactions:

1. CNS depressants (alcohol, opioids, benzodiazepines): Additive sedation
2. ACE inhibitors: Possible increased risk of angioedema
3. Thiazolidinediones (e.g., pioglitazone): May worsen fluid retention
4. Always inform your doctor about all medications.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date on the blister pack. Available by prescription in Pakistan.